PARVOKAN LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION

Authorised

- Derzsy's disease virus, strain H, Live
- Muscovy duck parvovirus, strain GM, Inactivated

Product identification

Medicine name:
PARVOKAN LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION
Parvokan

Active substance:
Derzsy's disease virus, strain H, Live
Muscovy duck parvovirus, strain GM, Inactivated

Target species:
Duck

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Derzsy's disease virus, strain H, Live

2.50 log10 50% cell culture infectious dose / 1.00 Dose

Muscovy duck parvovirus, strain GM, Inactivated
1.50 log10 serum neutralising unit(s) / 1.00 Dose

Pharmaceutical form:
Lyophilisate and suspension for suspension for injection

Withdrawal period by route of administration:
Subcutaneous use:

- **Duck**
  - All relevant tissues. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI01BH01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Germany

Package description:
Box of one 500-dose bottle of suspension and one 500-dose bottle of freeze-dried pellet
Box of ten 1,500-dose bottles of suspension and thirty 500-dose bottles of freeze-dried pellet
Box of ten 500-dose bottles of suspension and ten 500-dose bottles of freeze-dried pellet
Box of one 1,500-dose bottle of suspension and three 500-dose bottles of freeze-dried pellet

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:
6/05/2004

Manufacturing sites for batch release:
Boehringer Ingelheim Animal Health France

Responsible authority:
Paul-Ehrlich-Institut

Authorisation number:
PEI.V.01012.01.1

Date of authorisation status change:
18/12/2008

Reference member state:
France

Procedure number:
FR/V/0144/001

Concerned member states:
Germany Italy

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 3/09/2024
Download